Gilead, Merck Hepatitis C Rivalry Heats Up

By | October 20, 2015

Scalper1 News

Big biotech Gilead Sciences (GILD) got a price-target increase Tuesday as big pharma Merck (MRK) released new data on its hepatitis C regimen that could be a rival to Gilead’s blockbuster franchise. Oppenheimer analyst Wendy Lam lifted her price target on Gilead to 124 from 120, writing that after the stock’s considerable sell-off — it’s down 17% from its June 24 high — investors are due to revisit Gilead’s strong fundamentals. She acknowledged Scalper1 News

Scalper1 News